You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE

Skin and Soft Tissue Infections in Immunocompetent Patients Reviewed

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Laurie Barclay, MD
  • CME/CE Released: 4/13/2010
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 4/13/2011
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, dermatologists, surgeons, and other specialists caring for immunocompetent patients with SSTIs.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe indications and recommendations for antibiotic treatment of skin and soft tissue infections in immunocompetent patients.
  2. Describe other recommended management strategies for skin and soft tissue infections in immunocompetent patients.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor(s)

  • Brande Nicole Martin

    CME Clinical Editor, Medscape, LLC

    Disclosures

    Disclosure: Brande Nicole Martin has disclosed no relevant financial relationships.

CME Author(s)

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Laurie E. Scudder, MS, NP

    Accreditation Coordinator, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC; Nurse Practitioner, School-Based Health Centers, Baltimore City Public Schools, Baltimore, Maryland

    Disclosures

    Disclosure: Laurie E. Scudder, MS, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape News CME has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2009. Term of approval is for 1 year from this date. Each issue is approved for .25 Prescribed credits. Credit may be claimed for 1 year from the date of this issue.

    Note: Total credit is subject to change based on topic selection and article length.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-10-084-H01-P).

    Contact this provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME/CE

Skin and Soft Tissue Infections in Immunocompetent Patients Reviewed

Authors: News Author: Laurie Barclay, MD CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 4/13/2010

Valid for credit through: 4/13/2011

processing....

April 13, 2010 — Updated diagnostic and treatment strategies for immunocompetent patients with skin and soft tissue infections (SSTIs), especially community-acquired methicillin-resistant Staphylococcus aureus (MRSA), are described in a review published in the April 1 issue of American Family Physician.

"Superficial soft tissue infections are increasingly common in the outpatient setting," writes James Owen Breen, MD, from the University of North Carolina at Chapel Hill School of Medicine. "The diagnosis of skin infections increased nearly threefold in U.S. emergency departments from 1993 to 2005. A large increase in community acquired ...MRSA infections has prompted changes in the approach to ...SSTIs."

Because of the rising incidence of SSTIs, family clinicians must be familiar with how to manage these conditions. Complicated SSTIs include those with evidence of systemic toxicity, surgical wound infections; perianal infections; animal or human bites; necrotizing soft tissue infections; and SSTIs in immunocompromised patients.

Types of SSTIs

Purulent types of SSTI include abscess, folliculitis, furuncle, and carbuncle. An abscess is a collection of pus within the dermis, associated with erythema and fluctuance, of polymicrobial cause, often involving skin flora (staphylococci and streptococci) and organisms from adjacent mucous membranes. An abscess is characterized as a complicated SSTI if the perianal or perineal areas are affected.

Folliculitis is defined as purulence limited to the epidermis, usually in body areas prone to friction and heavy perspiration. A furuncle is purulence surrounding the hair follicles and extending to subcutaneous tissue, and a carbuncle is the coalescence of several furuncles. In immunocompetent patients, these types of SSTIs are caused by S aureus.

Nonpurulent SSTIs include cellulitis, erysipelas, and impetigo. Cellulitis has a well-demarcated border of erythema, warmth, edema, and pain, caused by streptococci without abscess formation or staphylococci with abscess. Complications may include lymphangitis, necrotizing infections, or gangrene.

Erysipelas is associated with intense erythema and a well-demarcated, painful plaque caused by beta-hemolytic streptococci. Impetigo is characterized by crusted exudates with pustules or vesicles, often seen in preschool-aged children or under conditions of poor hygiene, high humidity, or warm temperatures.

Treatment Options

The main treatment of uncomplicated abscesses measuring less than 5 cm in diameter is surgical drainage alone. Outcomes are similar when wounds are irrigated with tap water or sterile water.

Fever, tachycardia, hypotension, or other signs of systemic infection are red flags warning of the need for inpatient treatment. For patients with life-threatening or rapidly advancing infections, urgent surgical referral is required.

Local resistance and susceptibility patterns should determine choice of antimicrobial agents when these are indicated. For uncomplicated SSTIs without focal coalescence or trauma, beta-lactam antibiotics are the first-line treatments in settings where suspicion is low for MRSA.

When empiric coverage for MRSA is indicated for uncomplicated SSTIs, oral agents are preferred (eg, tetracyclines, trimethoprim/sulfamethoxazole, and clindamycin). In hospitalized patients, vancomycin is the first-line agent for MRSA. Linezolid, daptomycin, tigecycline, and other newer agents should be given only to patients who are refractory to or cannot tolerate vancomycin.

To date, evidence is insufficient to support use of nasal mupirocin or antibacterial body washes to eradicate the carrier state in patients with MRSA or their contacts. The mainstay of MRSA prevention is proper and frequent handwashing as well as other standard infection-control precautions.

Key Recommendations

Specific key clinical recommendations for practice, and their accompanying level of evidence rating, are as follows:

  • In patients with uncomplicated SSTIs, wound and blood cultures are not needed because results rarely change management decisions (level of evidence: C, based on retrospective analyses).
  • For uncomplicated SSTIs with abscesses measuring less than 5 cm in diameter, incision and drainage alone is often curative (level of evidence: A, based on retrospective chart review and randomized, double-blind trials).
  • For surgical drainage of SSTIs, clinical outcomes are no different for wound irrigation with tap water vs sterile water (level of evidence: A, based on prospective trials from urban pediatric emergency departments).
  • Clinicians should consider local prevalence and resistance patterns of MRSA and other pathogens when starting empiric antimicrobial therapy for uncomplicated SSTIs (level of evidence: C, based on expert opinion).
  • Eradicating the MRSA carrier state does not appear to be associated with a lower incidence of clinical MRSA infection (level of evidence: A, based on a randomized, double-blind trial and Cochrane review).

"Standard infection control precautions should be implemented and encouraged for all patients in ambulatory and inpatient settings, including proper and frequent handwashing, use of gloves when managing wounds, and contact precautions (e.g., use of gowns and gloves, grouping patients with similar infections) for patients with known or suspected MRSA infections," Dr. Breen concludes. "To prevent SSTIs, current consensus guidelines support proper foot care among patients with diabetes, tinea pedis, or pedal edema from venous insufficiency or lymphedema."

Dr. Breen has disclosed no relevant financial relationships.

Am Fam Physician. 2010;81:893-899. Abstract

Additional Resource

The Infectious Diseases Society of America offers practice guidelines for diagnosis and management of skin and soft tissue infections available online (Clin Infect Dis. 2005; 41:1373-406).

Clinical Context

SSTIs are on the rise among outpatients, with nearly tripled incidence in US emergency departments from 1993 to 2005. Family clinicians must therefore be familiar with how to manage SSTIs, including community acquired MRSA infections, which have also increased dramatically.

Purulent types of SSTI include abscess, folliculitis, furuncle, and carbuncle, whereas nonpurulent SSTIs include cellulitis, erysipelas, and impetigo. Complicated SSTIs are those causing systemic toxicity; surgical wound infections; perianal infections; animal or human bites; necrotizing soft tissue infections; and SSTIs in immunocompromised patients.

Study Highlights

  • When antibiotics are needed for SSTIs, specific agents should be chosen based on local patterns of resistance and susceptibility.
  • When suspicion is low for MRSA, beta-lactam antibiotics are the first-line treatments of uncomplicated SSTIs without focal coalescence or trauma.
  • For uncomplicated SSTIs when empiric coverage for MRSA is indicated, oral agents are preferred (eg, tetracyclines, trimethoprim/sulfamethoxazole, or clindamycin).
  • Vancomycin is the first-line agent for MRSA in hospitalized patients.
  • Use of linezolid, daptomycin, tigecycline, and other newer agents should be given only to patients who do not respond to or cannot tolerate vancomycin treatment.
  • Surgical drainage alone is indicated for uncomplicated abscesses less than 5 cm in diameter.
  • Wound and blood cultures are not needed for patients with uncomplicated SSTIs because results rarely change management.
  • Outcomes are similar for tap water vs sterile water wound irrigation.
  • Inpatient management is indicated for signs of systemic infection such as fever, tachycardia, or hypotension.
  • Urgent surgical referral is required for patients with life-threatening or rapidly advancing infections.
  • In patients with MRSA or their contacts, evidence to date does not support use of nasal mupirocin or antibacterial body washes to eradicate the carrier state.
  • Eradicating the MRSA carrier state does not appear to reduce clinical MRSA infection.
  • The mainstay of MRSA prevention is standard infection-control precautions including proper and frequent handwashing.

Clinical Implications

  • When antibiotics are needed for SSTIs, specific agents should be chosen based on local patterns of resistance and susceptibility. For uncomplicated SSTIs without focal coalescence or trauma, first-line treatment when suspicion is low for MRSA is a beta-lactam antibiotic.
  • Wound and blood cultures are not needed for patients with uncomplicated SSTIs. Surgical drainage alone is indicated for uncomplicated abscesses less than 5 cm in diameter. Inpatient management is indicated for signs of systemic infection, and urgent surgical referral is required for patients with life-threatening or rapidly advancing infections.

CME/CE Test